Loading…

Cytotoxic Proteins Combined with Prodigiosin Obtained from Serratia marcescens Have Both Broad and Selective Cytotoxic Activity on Tumor Cells

Cytotoxic proteins and prodigiosin obtained from Serratia marcescens strains are known to induce tumor cell death, nevertheless its combination has not been studied. In this paper we evaluate the combined effects of these molecules in a panel of tumor cell lines. The results showed a marked inhibito...

Full description

Saved in:
Bibliographic Details
Published in:Journal of chemotherapy (Florence) 2006-04, Vol.18 (2), p.172-181
Main Authors: Abrahantes-Pérez, M.C., Reyes-González, J., Véliz Ríos, G., Bequet-Romero, M., Gómez Riera, R., Anais Gasmury, C., Huerta, V., González, L.J., Canino, C., Garcia, J., Váldez, J., Reyes, B., Váldes, R., Martínez, E.
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Cytotoxic proteins and prodigiosin obtained from Serratia marcescens strains are known to induce tumor cell death, nevertheless its combination has not been studied. In this paper we evaluate the combined effects of these molecules in a panel of tumor cell lines. The results showed a marked inhibitory effect on the growth of tumor cell lines derived from tumors (i.e., melanoma) which are highly resistant to conventional anticancer drugs, while normal cells were less sensitive than tumor cells. TUNEL (TdT-mediated dUTP nick end labeling) and electrophoresis of HEp-2 cell DNA treated with MG2327 preparation [containing the P50 protein belonging to the serralysins and prodigiosin, from S. marcescens CMIB4202] showed a pattern of DNA fragments typically associated with apoptosis. Interestingly, prodigiosin enhanced by 1.6-fold the cytotoxic effect of P50 when acting in combination on HEp-2 cells. The broad cytotoxic activity of the combination on tumor cells as well as its selectivity open new frontiers in cancer therapy.
ISSN:1120-009X
1973-9478
DOI:10.1179/joc.2006.18.2.172